684 related articles for article (PubMed ID: 18657016)
1. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.
Kim T; Han N; Sohn M; Oh JM; Lee EK; Ji E; Kim IW
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):438-44. PubMed ID: 25348905
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic biomarkers in drug labels: what do they tell us?
Tutton R
Pharmacogenomics; 2014 Feb; 15(3):297-304. PubMed ID: 24533709
[TBL] [Abstract][Full Text] [Related]
4. Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels.
Wang B; Canestaro WJ; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1938-44. PubMed ID: 25317785
[TBL] [Abstract][Full Text] [Related]
5. Molecular biomarkers: a US FDA effort.
Hong H; Goodsaid F; Shi L; Tong W
Biomark Med; 2010 Apr; 4(2):215-25. PubMed ID: 20406066
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
[TBL] [Abstract][Full Text] [Related]
7. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
Vivot A; Boutron I; Ravaud P; Porcher R
Genet Med; 2015 Sep; 17(9):733-8. PubMed ID: 25521333
[TBL] [Abstract][Full Text] [Related]
8. Sources of drug information: FDA-approved labeling and other official FDA sources.
Lindstrom JA
Dermatol Ther; 2009; 22(3):246-56. PubMed ID: 19453349
[TBL] [Abstract][Full Text] [Related]
9. A review of patient-reported outcome labels in the United States: 2006 to 2010.
Gnanasakthy A; Mordin M; Clark M; DeMuro C; Fehnel S; Copley-Merriman C
Value Health; 2012 May; 15(3):437-42. PubMed ID: 22583453
[TBL] [Abstract][Full Text] [Related]
10. Should pharmacogenomic studies be required for new drug approval?
Relling MV; Hoffman JM
Clin Pharmacol Ther; 2007 Mar; 81(3):425-8. PubMed ID: 17339872
[TBL] [Abstract][Full Text] [Related]
11. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling.
Willy ME; Li Z
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):201-6. PubMed ID: 15255086
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C
Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752
[TBL] [Abstract][Full Text] [Related]
13. Are "off-labels" legal?
Price EC
Mich Health Hosp; 1998; 34(6):20-1. PubMed ID: 10187136
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.
Schuck RN; Grillo JA
AAPS J; 2016 May; 18(3):573-7. PubMed ID: 26912182
[TBL] [Abstract][Full Text] [Related]
16. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
[TBL] [Abstract][Full Text] [Related]
17. 2000-2001 food label and package survey: an update on prevalence of nutrition labeling and claims on processed, packaged foods.
Legault L; Brandt MB; McCabe N; Adler C; Brown AM; Brecher S
J Am Diet Assoc; 2004 Jun; 104(6):952-8. PubMed ID: 15175594
[TBL] [Abstract][Full Text] [Related]
18. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs.
Pediatrics; 1996 Jul; 98(1):143-5. PubMed ID: 8668390
[TBL] [Abstract][Full Text] [Related]
19. Status of nutrition labeling, health claims, and nutrient content claims for processed foods: 1997 Food Label and Package Survey.
Brecher SJ; Bender MM; Wilkening VL; McCabe NM; Anderson EM
J Am Diet Assoc; 2000 Sep; 100(9):1057-62. PubMed ID: 11019354
[TBL] [Abstract][Full Text] [Related]
20. Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
Goodsaid F; Frueh FW
Environ Mol Mutagen; 2007 Jun; 48(5):354-8. PubMed ID: 17567848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
